^
Association details:
| Biomarker: | HER-2 amplification + KRAS G12D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
Excerpt:
This case report presents a 58-year-old man with HER2-amplified mCRC and a KRAS G12D mutation...He subsequently derived a clinical benefit with metastatic lung disease regression on trastuzumab emtansine (T-DM1). He eventually experienced disease progression in the liver after 6 every-3-week cycles.
DOI:
10.6004/jnccn.2019.7371
